An overview of ICIs as a new treatment for hepatocellular carcinoma
Linda Qu, Assistant Editor at Tech Science Press, shared a recent article by Xuan-Yu Gu on LinkedIn:
“Review Article Series: Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects.
This review provides an overview of ICIs as a new treatment for HCC, demonstrating some success in promoting the tumor immune response.
However, drug resistance and adverse reactions remain important considerations that must be addressed.
As tailored treatment plans evolve, the prospect of immunotherapy for HCC is expected to grow, offering new opportunities for improved patient outcomes.”
Authors: Xuan-Yu Gu, Jin-Long Huo, Zhi-Yong Yu, Ji-Chang Jiang, Ya-Xuan Xu and Li-Jin Zhao
For more updates, follow OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023